Clinical Trial Update: Safety Study of Respiratory Syncytial Virus (RSV)-Fusion (F) Protein Particle Vaccine [Phase 1]

View source ↗

Summary

This clinical trial update reports that a Phase 1 safety study of Novavax's RSV-F protein particle vaccine for Respiratory Syncytial Virus infection has been co…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• RSV-F protein particle vaccine (RSV fusion (F) protein particle vaccine)

Snippet

Sponsor: Novavax | Conditions: Respiratory Syncytial Virus Infections | Phase 1 | Status: COMPLETED